Azelastine/mometasone - Hanlim Pharmaceutical

Drug Profile

Azelastine/mometasone - Hanlim Pharmaceutical

Alternative Names: Mometasone/azelastine; Nasaflex Nasal Spray

Latest Information Update: 10 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanlim Pharmaceutical
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Phthalazines; Pregnadienediols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis

Most Recent Events

  • 10 Oct 2013 Registered and launched (prior to 10 October 2013) for Perennial allergic rhinitis in South Korea (Intranasal)
  • 01 Nov 2012 Hanlim Pharmaceutical completes its phase III trial in Perennial allergic rhinitis in South Korea (NCT01470053)
  • 01 Mar 2011 Phase-III clinical trials in Perennial allergic rhinitis in South Korea (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top